title: Novel drug delivery strategies for the treatment of inflammatory bowel disease.
abstract: Inflammatory bowel disease (IBD) encompasses two idiopathic inflammatory diseases of the intestinal tract: Crohn's disease and ulcerative colitis. Existing therapy for IBD consists mainly of orally or rectally administered small drug molecules, such as 5-aminosalicylates and corticosteroids, or potent systemic immune suppressants. IBD presents a challenging target for drug delivery, particularly by the oral route, as, contrary to most therapeutic regimens, minimal systemic absorption and maximal intestinal wall drug levels are desired. Several delivery strategies are employed to achieve this goal, including the chemical modification of the drug molecules, the use of controlled- and delayed-release formulations and the use of bioadhesive particles. The goal of this review is to summarise existing IBD therapy and examine novel approaches in intestinal drug delivery.
authors.affiliation: University of Michigan Department of Pharmaceutical Sciences, College of Pharmacy, Ann Arbor, MI 48109-1065, USA.
authors.forename: Filippos
authors.initials: F
authors.lastname: Kesisoglou
authors.forename: Ellen M
authors.initials: EM
authors.lastname: Zimmermann
mesh_terms: D016503:Drug Delivery Systems / Q000379:methods*; D005765:Gastrointestinal Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D015316:Genetic Therapy; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000628:therapy
chemical_list: D005765:Gastrointestinal Agents